期刊文献+

美沙拉嗪栓剂治疗溃疡性结肠炎的效果研究 被引量:2

Observation on Mesalamine Suppository Application Efficacy in Treatment of Ulcerative Colitis
下载PDF
导出
摘要 目的:研究溃疡性结肠炎应用美沙拉嗪栓剂治疗的临床疗效。方法选取我院2013年4月~2014年4月间收治的36例溃疡性结肠炎患者,对照组接受美沙拉嗪肠溶片口服治疗,治疗组同时接受美沙拉嗪栓剂治疗,比较两组临床疗效。结果治疗组总有效率(92.86%)、黏膜病变缓解率(92.86%)与对照组(81.82%)、(77.27%)相比较高,两组患者临床疗效差异显著,有统计学意义(P〈0.05)。结论溃疡性结肠炎应用美沙拉嗪栓剂治疗能够增加肠道药物浓度,缩短康复进程,预防不良反应,安全性高,值得推广。 Objective Clinical efficacy of mesalamine suppository in treatment of ulcerative colitis is to be investigated. Methods Choose 36 ulcerative colitis patients who are treated in hospital from April 2013 to April 2014,patients in control group are given mesalamine enteric-coated tablets treatment;while patients in study group are given additional mesalamine suppository treatment,and then observe and compare treatment efficacy in these two groups. Results Treatment efficacy(92.86%)and mucosal disease remission rate(92.86%)in study group are higher than counterparts in control group(81.82%),(77.27%); there is differential between study group and such a differential has statistic value(P〈0.05). Conclusion Mesalamine suppository is of efficacy in treatment of ulcerative colitis;it is conducive to increasing intestinal medicine concentration,shortening treatment course and preventing from side effect with safety;therefore,such a treatment method is quite worthwhile to be promoted widespread.
作者 邵丽
出处 《中国卫生标准管理》 2015年第9期243-244,共2页 China Health Standard Management
关键词 溃疡性结肠炎 美沙拉嗪 临床效果 Ulcerative Colitis Mesalamine Clinical efficacy
  • 相关文献

参考文献3

二级参考文献35

  • 1张秋瓒,刘晓红.炎性肠病的免疫及生物治疗进展[J].实用医学杂志,2004,20(9):1080-1081. 被引量:5
  • 2陈治水,危北海,张万岱.溃疡性结肠炎中西医结合诊治方案(草案)[J].中国中西医结合杂志,2004,24(11):1052-1055. 被引量:180
  • 3Christensen LA.5-Aminosalicylic acid conmtaining drugs.Delivery,fate,and possible clinical implications in man[J].Dan Med Bull,2000,47(1):20-41.
  • 4Hanauer SBReview article:high-dose aminosalicylatestoinduce and maintain remissions in ulcerative colitis[J].Aliment Pharma-col Ther,2006,24(Suppl 3):37-40.
  • 5Sandborn WJ,Hanauer SB.Systematic review:the pharmacoki-neUe priles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis[J].Aliment Pharmacol Ther,2003,17(1):29-42.
  • 6中华医学会消化病学分会炎症性肠病协作组,欧阳钦,胡品津,钱家鸣,郑家驹,胡仁伟.对我国炎症性肠病诊断治疗规范的共识意见(2007年,济南)[J].中华消化杂志,2007,27(8):545-550. 被引量:1021
  • 7Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis, 2004,10(3):286-299.
  • 8Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis, 2004,10(5):646-651.
  • 9Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalazine 4.8g1day (800 mg tablets)compared to 2.4/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol, 2007,21~12):827- 834.
  • 10Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther, 2007,26(2):205-215.

共引文献53

同被引文献19

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部